Pneumococcal conjugate vaccine: review of cost–effectiveness studies in Australia, North America and Europe

References

• Whitney CG, Moore MR. Direct and indirect effectiveness and safety of pneumococcal conjugate vaccine in practice. In: Pneumococcal Vaccines: The Impact of Conjugate Vaccine. Siber GR, Klugman KP, Makela PH (Eds). ASM Press, DC, USA, 353–368 (2008).
   Google Scholar
• Zimmerman RK, Jackson RE. Vaccine policy decisions: tension between science, cost–effectiveness and consensus? Am. Fam. Physician63(10), 1919–1923 (2001).
   PubMed Web of Science ®Google Scholar
• Jewett P. President’s column – news update. American Academy of Pediatrics California.2000(4), Chapter 1 (2000).
   Google Scholar
• Ray GT. Pneumococcal conjugate vaccine: economic issues of the introduction of a new childhood vaccine. Expert Rev. Vaccines1(1), 65–74 (2002).
   PubMedGoogle Scholar
• Hueston WJ, Mainous AG 3rd, Brauer N. Predicting cost-benefits before programs are started: looking at conjugate vaccine for invasive pneumococcal infections. J. Community Health25(1), 23–33 (2000).
   PubMed Web of Science ®Google Scholar
• Lieu TA, Ray GT, Black SB et al. Projected cost–effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA283(11), 1460–1468 (2000).
   PubMed Web of Science ®Google Scholar
• Weycker D, Richardson E, Oster G. Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs. Am. J. Manag. Care6(10 Suppl.), S526–S535 (2000).
   PubMed Web of Science ®Google Scholar
• De Wals P, Petit G, Erickson LJ et al. Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada. Vaccine21(25–26), 3757–3764 (2003).
   PubMed Web of Science ®Google Scholar
• Ess SM, Schaad UB, Gervaix A, Pinosch S, Szucs TD. Cost–effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine21(23), 3273–3281 (2003).
   PubMed Web of Science ®Google Scholar
• Claes C, Graf von der Schulenburg JM. Cost–effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany. Pharmacoeconomics21(8), 587–600 (2003).
   PubMed Web of Science ®Google Scholar
• McIntosh ED, Conway P, Willingham J, Lloyd A. The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine. Vaccine21(19–20), 2564–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Lebel MH, Kellner JD, Ford-Jones EL et al. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada. Clin. Infect. Dis.36(3), 259–268 (2003).
   PubMed Web of Science ®Google Scholar
• Asensi F, De Jose M, Lorente M et al. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value Health7(1), 36–51 (2004).
   PubMed Web of Science ®Google Scholar
• Wisloff T, Abrahamsen TG, Bergsaker MA et al. Cost–effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine24(29–30), 5690–5699 (2006).
   PubMed Web of Science ®Google Scholar
• Moore D, Bigham M, Patrick D. Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia. Can. Commun. Dis. Rep.29(11), 97–104 (2003).
   PubMedGoogle Scholar
• Bos JM, Rumke H, Welte R, Postma MJ. Epidemiologic impact and cost–effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin. Ther.25(10), 2614–2630 (2003).
   PubMed Web of Science ®Google Scholar
• Melegaro A, Edmunds WJ. Cost–effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine22(31–32), 4203–4214 (2004).
   PubMed Web of Science ®Google Scholar
• Navas E, Salleras L, Gisbert R et al. Cost–benefit and cost–effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain). Vaccine23(17–18), 2342–2348 (2005).
   PubMed Web of Science ®Google Scholar
• Salo H, Sintonen H, Pekka NJ et al. Economic evaluation of pneumococcal conjugate vaccination in Finland. Scand. J. Infect. Dis.37(11–12), 821–832 (2005).
   PubMed Web of Science ®Google Scholar
• Butler JR, McIntyre P, MacIntyre CR et al. The cost–effectiveness of pneumococcal conjugate vaccination in Australia. Vaccine22(9–10), 1138–1149 (2004).
   PubMed Web of Science ®Google Scholar
• Marchetti M, Colombo GL. Cost–effectiveness of universal pneumococcal vaccination for infants in Italy. Vaccine23(37), 4565–4576 (2005).
   PubMed Web of Science ®Google Scholar
• Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination – a review (2002–2006). Vaccine25(8), 1355–1367 (2007).
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J.19(3), 187–195 (2000).
   PubMed Web of Science ®Google Scholar
• Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med.344(6), 403–409 (2001).
   PubMed Web of Science ®Google Scholar
• Fireman B, Black SB, Shinefield HR et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr. Infect. Dis. J.22(1), 10–16 (2003).
   PubMed Web of Science ®Google Scholar
• Black SB, Shinefield HR, Ling S et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J.21(9), 810–815 (2002).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Notice to readers: updated recommendations for use of pneumococcal conjugate vaccine: reinstatement of third dose. MMWR Morb. Mortal Wkly Rep.53(26), 589–590 (2004).
   Google Scholar
• Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Cost–Effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds.). Oxford University Press, NY, USA, 214–246 (1996).
   Google Scholar
• Viscusi WK. Discounting health effects for medical decisions. In: Valuing Health Care: Costs, Benefit, and Effectiveness of Phamraceuticals and Other Medical Technologies. Sloan FA (Ed.). Cambridge University Press, Cambridge, UK, 125–147 (1995).
   Google Scholar
• Torgerson DJ, Raftery J. Economic notes. Discounting. BMJ319(7214), 914–915 (1999).
   PubMedGoogle Scholar
• Gravelle H, Brouwer W, Niessen L, Postma M, Rutten F. Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ.16(3), 307–317 (2007).
   PubMed Web of Science ®Google Scholar
• Birks S. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics24(12), 1273–1274 (2006).
   PubMed Web of Science ®Google Scholar
• Bos JM, Postma MJ, Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics23(7), 639–649 (2005).
   PubMed Web of Science ®Google Scholar
• Lazaro A. Theoretical arguments for the discounting of health consequences: where do we go from here? Pharmacoeconomics20(14), 943–961 (2002).
   PubMed Web of Science ®Google Scholar
• Brouwer WB, Niessen LW, Postma MJ, Rutten FF. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ331(7514), 446–448 (2005).
   PubMed Web of Science ®Google Scholar
• Gold MR, Patrick DL, Torrance GW et al. Identifying and valuing outcomes. In: Cost–Effectiveness in Health and Medicine. Gold MR, Seigel JE, Russell LB Weinstein MC (Eds). Oxford University Press, NY, USA, 82–134 (1996).
   Google Scholar
• Prosser LA, Ray GT, O’Brien M et al. Preferences and willingness to pay for health States prevented by pneumococcal conjugate vaccine. Pediatrics113(2), 283–290 (2004).
   PubMed Web of Science ®Google Scholar
• Cheng AK, Rubin HR, Powe NR et al. Cost–utility analysis of the cochlear implant in children. JAMA284(7), 850–856 (2000).
   PubMed Web of Science ®Google Scholar
• Bennett JE, Sumner W, Downs SM, Jaffe DM. Parents’ utilities for outcomes of occult bacteremia. Arch. Pediatr. Adolesc. Med.154(1), 43–48 (2000).
   PubMedGoogle Scholar
• Oostenbrink R, A Moll HA, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J. Clin. Epidemiol.55(8), 791–799 (2002).
   PubMed Web of Science ®Google Scholar
• Oh PI, Maerov P, Pritchard D et al. A cost–utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Clin. Ther.18(1), 160–182 (1996).
   PubMed Web of Science ®Google Scholar
• Pepper PV, Owens DK. Cost–effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps. Clin. Infect. Dis.30(1), 157–164 (2000).
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Baxter R et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr. Infect. Dis. J.23(6), 485–489 (2004).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. MMWR Morb. Mortal. Wkly. Rep.54(36), 893–897 (2005).
   PubMedGoogle Scholar
• Lexau CA, Lynfield R, Danila R et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA294(16), 2043–2051 (2005).
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Poehling KA, Nuorti JP et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics118(3), 865–873 (2006).
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Nuorti JP, Arbogast PG et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet369(9568), 1179–1186 (2007).
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Dagan R, Makela PH. Nasopharyngeal carriage. In: Pneumococcal Vaccines: The Impact of Conjugate Vaccine. Siber GR, Klugman KP, Makela PH (Eds). ASM Press, DC, USA, 279–300 (2008).
   Google Scholar
• Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB. Cost–effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr. Infect. Dis. J.25(6), 494–501 (2006).
   PubMed Web of Science ®Google Scholar
• McIntosh ED, Conway P, Willingham J, Hollingsworth R, Lloyd A. Pneumococcal pneumonia in the UK – how herd immunity affects the cost–effectiveness of 7-valent pneumococcal conjugate vaccine (PCV). Vaccine23(14), 1739–1745 (2005).
   PubMed Web of Science ®Google Scholar
• Black SB, Shinefield HR, Ray PM, Fireman BH. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: impact on pneumonia, otitis media, and an update on invasive disease results of the Northern California Kaiser Permanente efficcacy trial. Presented at: 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, 24–27 September 1998 (Abstract 1398).
   Google Scholar
• Luce BR, Manning WG, Siegel JE, Lipscomb J. Estimating costs in cost–effectiveness analysis. In: Cost–effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds). Oxford University Press, NY, USA, 176–213 (1996).
   Google Scholar
• Garber AM, Weinstein MC, Torrance GW, Kamlet MS. Theoretical foundations of cost–effectiveness analysis. In: Cost–Effectiveness in Health and Medicine. Gold MR, Seigel JE, Russell LB, Weinstein MC (Eds). Oxford University Press, NY, USA, 25–53 (1996).
   Google Scholar
• Lieu TA, Cochi SL, Black SB et al. Cost–effectiveness of a routine varicella vaccination program for US children. JAMA271(5), 375–381 (1994).
   PubMed Web of Science ®Google Scholar
• Margolis HS, Coleman PJ, Brown RE et al. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA274(15), 1201–1208 (1995).
   PubMed Web of Science ®Google Scholar
• Stone PW, Teutsch S, Chapman RH et al. Cost–utility analyses of clinical preventive services: published ratios, 1976–1997. Am. J. Prev. Med.19(1), 15–23 (2000).
   PubMed Web of Science ®Google Scholar
• Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn’t it increase at the rate of inflation? Arch. Intern. Med.163(14), 1637–1641 (2003).
   PubMed Web of Science ®Google Scholar
• Grosse SD. Assessing cost–effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev. Pharmacoeconomics Outcomes Res.8(2), 165–178 (2008).
   PubMedGoogle Scholar
• Birch S, Gafni A. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost–effectiveness threshold. J. Health Serv. Res. Policy.11(1), 46–51 (2006).
   PubMedGoogle Scholar
• Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics24(11), 1121–1131 (2006).
   PubMed Web of Science ®Google Scholar
• Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc. Sci. Med.62(9), 2091–2100 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou F, Kyaw MH, Shefer A, Winston CA, Nuorti JP. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch. Pediatr. Adolesc. Med.161(12), 1162–1168 (2007).
   PubMed Web of Science ®Google Scholar
• Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997–2004. Pediatrics121(2), 253–260 (2008).
   PubMed Web of Science ®Google Scholar
• Poehling KA, Szilagyi PG, Grijalva CG et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics119(4), 707–715 (2007).
   PubMed Web of Science ®Google Scholar
• Sinha A, Levine O, Knoll MD, Muhib F, Lieu TA. Cost–effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet369(9559), 389–396 (2007).
   PubMed Web of Science ®Google Scholar
• Sinha A, Ray GT. Pharmacoeconomics of pneumococcal conjugate vaccines. In: Pneumococcal Vaccines: The Impact of Conjugate Vaccine Siber G, Klugman KP, Makela PH (Eds). ASM Press, DC, USA, 387–403 (2008).
   Google Scholar